SCHEMBL7236152

SCHEMBL7236152

CCC(Br)c1ccccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.46
TSHR P16473 2/20 0.39
ACHE P22303 1/20 0.39
MC4R P32245 1/20 0.39
ALDH1A1 P00352 2/20 0.37
ACP3 P15309 1/20 0.36
CYP2D6 P10635 3/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
SLC6A3 Q01959 3/20 0.35
KCNH2 Q12809 2/20 0.35
CYP3A4 P08684 2/20 0.35
SLC22A2 O15244 1/20 0.35
SLC22A1 O15245 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
ADRA2A P08913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11719990 0.85 TSHR (0.44) ESR1TSHRALDH1A1CYP2D6SLC6A2
SCHEMBL28532178 0.82 ESR1 (0.46) ESR1TSHRACHEMC4RALDH1A1
SCHEMBL6221831 0.77 ESR1 (0.46) ESR1TSHRACHEMC4RALDH1A1
SCHEMBL10455676 0.77 TSHR (0.39) TSHRALDH1A1CYP2C19CYP2C9LMNA
SCHEMBL216837 0.77 HTT (0.40) TSHRALDH1A1CYP2D6CYP3A4CYP2C19
SCHEMBL28339211 0.77 ESR1 (0.38) ESR1ALDH1A1KCNH2NPSR1MEN1
SCHEMBL9656285 0.76 ESR1 (0.50) ESR1TSHRACHEMC4RALDH1A1
SCHEMBL6547004 0.76 ESR1 (0.50) ESR1TSHRACHEMC4RACP3
SCHEMBL31538069 0.76 ESR1 (0.50) ESR1TSHRACHEMC4RALDH1A1
SCHEMBL6643908 0.76 NISCH (0.44) TSHRMC4RCYP2D6SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534496-B1 Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or TAKEDA CHEMICAL INDUSTRIES, INC. (JP) 2003-03-18 US disclosed
EP-0975624-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS Takeda Chemical Industries, Ltd. (JP) 2000-02-02 EP disclosed
WO-1998046590-A1 THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-10-22 WO disclosed
EP-0682663-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-22 EP disclosed